Hyperimmune immunoglobulin for people with COVID-19-Reference-Cited by-同舟云学术

Hyperimmune immunoglobulin for people with COVID-19

Published:2023-01-26 Issue:1 Volume:2023 Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Kimber Catherine¹,Valk Sarah J²,Chai Khai Li³,Piechotta Vanessa⁴,Iannizzi Claire⁵,Monsef Ina⁴,Wood Erica M³,Lamikanra Abigail A⁶,Roberts David J¹,McQuilten Zoe³,So-Osman Cynthia⁷⁸,Estcourt Lise J⁹,Skoetz Nicole⁴

Affiliation:

1. Systematic Review Initiative; NHS Blood and Transplant; Oxford UK

2. Jon J van Rood Center for Clinical Transfusion Research; Sanquin/Leiden University Medical Center; Leiden Netherlands

3. Transfusion Research Unit, School of Public Health and Preventive Medicine; Monash University; Melbourne Australia

4. Cochrane Haematology, Department I of Internal Medicine; Faculty of Medicine and University Hospital Cologne, University of Cologne; Cologne Germany

5. Cochrane Haematology, Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne; University of Cologne; Cologne Germany

6. Clinical, Research and Development; NHS Blood and Transplant; Oxford UK

7. Erasmus Medical Centre; Rotterdam Netherlands

8. Unit Transfusion Medicine; Sanquin Blood Supply Foundation; Amsterdam Netherlands

9. Haematology/Transfusion Medicine; NHS Blood and Transplant; Oxford UK

Publisher

Wiley

Subject

Pharmacology (medical)

Reference131 articles.

1. Hyperimmune anti-COVID-19 IVIG (C-IVIG) treatment in severe and critical COVID-19 patients: a phase I/II randomized control trial;Ali;EClinical Medicine,2021

2. Pharmacokinetics and safety of XAV-19, a swine glyco-humanized polyclonal anti-SARS-CoV-2 antibody, for COVID-19-related moderate pneumonia: a randomized, double-blind, placebo-controlled, phase IIa study;Gaborit;Antimicrobial Agents and Chemotherapy,2021

3. Treatment of patients with coronavirus infection with immunoglobulin who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2020-002542-16-GR

4. Inpatient treatment with anti-coronavirus immunoglobulin (ITAC) clinicaltrials.gov/show/NCT04546581

5. Hyperimmune immunoglobulin for hospitalised patients with COVID-19 (ITAC): a double-blind, placebo-controlled, phase 3, randomised trial;The ITAC (INSIGHT 013) Study Group;Lancet,2022

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Intravenous immunoglobulin as a potential treatment for long COVID;Expert Opinion on Biological Therapy;2023-12-02

2. Managing blood supplies during natural disasters, humanitarian emergencies, and pandemics: lessons learned from COVID-19;Expert Review of Hematology;2023-05-09

3. For adults with moderate/severe COVID-19, what are the effects of hyperimmune immunoglobulin, specifically equine polyclonal antibodies (EpAbs)?;Cochrane Clinical Answers;2023-01-31

4. What are the benefits and harms of hyperimmune immunoglobulin (hIVIG) from human plasma for treating adults with moderate/severe COVID-19?;Cochrane Clinical Answers;2023-01-31